Author + information
The aim of this study is to investigate the plasmatic count and percentage of platelet-derived microparticles (PMP) in patients with hypertension and hyperlipidemia. And the relationship between PMP and clinical characteristics.
The study included 18 patients with hypertension and hyperlipidemia and 14 healthy subjects. Flow cytometry assay were used to measure the count and percentages of platelet-derived microparticles marked by both CD31 and CD42b. Clinical characteristics containing routine blood count, lipids and biochemical test were recorded. The patients only have simple hypertension and hyperlipidemia without diabetes, coronary heart disease or any other cardiovascular diseases.
The count and percentages of platelet-derived microparticles in healthy group (n=14) were respectively CD31+CD42b+PMP/μl 5.18 (5th to 75th percentile 3.20-7.07) however in patients with hypertension and hyperlipidemia (n=18), they were CD31+CD42b+PMP/μl 10.68 (25th to 75th percentile 6.49-16.81). Compared with healthy group, patients significantly increased (P=0.012). Furthermore, platelet-derived microparticles CD31+CD42b+ was positively correlated with platelet count (R=0.49 P=0.024).
Platelet-derived microparticles CD31+CD42b+ significantly raised in patients with hypertension and hyperlipidemia, which may be a new potential marker to reflect coagulation function in patients with hypertension and hyperlipidemia.